Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2743PDF: 823HTML: 6499Untitled: 206Untitled: 169Untitled: 170Untitled: 192 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4542PDF: 2732HTML: 2246 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2695PDF: 1071HTML: 3254 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2740PDF: 980HTML: 5497 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2798PDF: 1391HTML: 3038Cover Letter: 182 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3232PDF: 1430HTML: 3978 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3831PDF: 1442HTML: 9172Untitled: 259Untitled: 163Untitled: 149Untitled: 145Untitled: 163Untitled: 316 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2511PDF: 838HTML: 17444Fig1 Caligaris: 145Fig.2 Caliga: 176 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3962PDF: 1012HTML: 3556Untitled: 164Cneo. Fig.1: 99Untitled: 89Untitled: 112Untitled: 114 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3154PDF: 905HTML: 2927 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3209PDF: 1310HTML: 2610 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2434PDF: 817HTML: 8790Efremov 1: 205Efremov 2: 165 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2171PDF: 1003HTML: 1972Characteristic of study group: 177 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2132PDF: 770HTML: 1606Figure 1: 163Table 1: 186 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2974PDF: 836HTML: 7150Kost Fig1: 164Kost Fig 2: 156Kost Fig3: 151Kost Fig 4: 169Kost Fig5: 167Kost fig 6: 151 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8880PDF: 5960HTML: 87459Fig.1b: 164Fig.1c: 165Fig.2a: 156Fig.2b: 161Fig.4: 169Fig.2c: 158Fig.3: 163Tab.1: 212Tab.2: 191Tab.3: 177Tab.4: 199Fig1a: 158 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3763PDF: 729HTML: 1826 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4295PDF: 874HTML: 1299Table1: 165 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2401PDF: 760HTML: 1721 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2752PDF: 1192HTML: 2666Figure 1: 147 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2013PDF: 1088HTML: 7671cover letter paper final AML: 192 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2516PDF: 707HTML: 2282 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2211PDF: 1296HTML: 17058Bassan Fig.1: 133Bassan Fig.2: 131Bassan Fig.4: 126Fig.3: 164 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4562PDF: 1284HTML: 1889Untitled: 166Untitled: 163 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3420PDF: 851HTML: 1622figure 1: 149Untitled: 173 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3464PDF: 1442HTML: 4296CoverLetter: 167Figure1: 176 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
1817PDF: 873HTML: 1744Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 143 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1134PDF: 725HTML: 1331Figure 1: 162Figure 2: 159







